Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …
Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022
S Kietaibl, A Ahmed, A Afshari… - European Journal of …, 2023 - journals.lww.com
Guidelines Management of severe peri-operative bleeding: Guidelines from the European
Society of Anaesthesiology and Intensive Care
Society of Anaesthesiology and Intensive Care
Persistent endotheliopathy in the pathogenesis of long COVID syndrome
H Fogarty, L Townsend, H Morrin… - … of thrombosis and …, 2021 - Wiley Online Library
Background Persistent symptoms including breathlessness, fatigue, and decreased exercise
tolerance have been reported in patients after acute SARS‐CoV‐2 infection. The biological …
tolerance have been reported in patients after acute SARS‐CoV‐2 infection. The biological …
The impact of COVID-19 disease on platelets and coagulation
GD Wool, JL Miller - Pathobiology, 2021 - karger.com
Abstract Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some
patients develop a severe proinflammatory state which can be associated with a unique …
patients develop a severe proinflammatory state which can be associated with a unique …
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Abstract Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …
Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches
Y Jin, W Ji, H Yang, S Chen, W Zhang… - Signal transduction and …, 2020 - nature.com
On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19) was declared a
pandemic by the World Health Organization. As of 4 August 2020, more than 18 million …
pandemic by the World Health Organization. As of 4 August 2020, more than 18 million …
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Background An important feature of severe acute respiratory syndrome coronavirus 2
pathogenesis is COVID-19-associated coagulopathy, characterised by increased thrombotic …
pathogenesis is COVID-19-associated coagulopathy, characterised by increased thrombotic …
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
The core pathology of coronavirus disease 2019 (COVID-19) is infection of airway cells by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive …
Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)
AR Bourgonje, AE Abdulle, W Timens… - The Journal of …, 2020 - Wiley Online Library
Abstract Angiotensin‐converting enzyme 2 (ACE2) has been established as the functional
host receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus …
host receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus …